Research Topics
| John F BarrettSummaryAffiliation: Merck Research Laboratories Country: USA Publications
| Collaborators
|
Detail Information
Publications
MRSA--what is it, and how do we deal with the problem?John F Barrett
Merck Research Laboratories, 126 E Lincoln Avenue, Rahway, NJ 07065, USA
Expert Opin Ther Targets 9:253-65. 2005..Action must be taken to contain and eradicate MRSA through a combination of infection control, the development of novel anti-MRSA agents, development of vaccines and other non-traditional approaches of intervention...
Empirical antibacterial drug discovery--foundation in natural productsSheo B Singh
Natural Products Chemistry, RY80Y 350, Merck Research Laboratories, P O 2000, Rahway, NJ 07065, USA
Biochem Pharmacol 71:1006-15. 2006..This commentary provides an overview of current antibiotic leads and their mechanism of action, and highlights tools that can be applied to the discovery of new antibiotics...
Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutationsLaura E Lawrence
BMSPRI, Infectious Diseases, Department of Microbilogy, Bristol Myers Squibb, Wallingford, Connecticut 06492, USA
Antimicrob Agents Chemother 46:191-5. 2002..7 and 61.6 mg/kg/day. BMS-284756 was more potent than levofloxacin and equipotent with moxifloxacin against ISP794 both in vitro and in vivo, while BMS-284756 was more potent than levofloxacin and moxifloxacin against 2C6(1)-1...
American Society for Microbiology-103rd General Meeting. 18-22 May 2003, Washington DC, USAJohn F Barrett
Merck Research Laboratories, Rahway, NJ 07065-0900, USA
IDrugs 6:639-42. 2003
Antibacterial drug discovery & development summitJohn F Barrett
Merck Research Laboratories, Rahway, NJ, USA
Expert Opin Investig Drugs 13:715-21. 2004..In addition, areas for basic research and development included metallo-beta-lactamases, ribosomal structural studies and phage-selected targets were described...
Recent developments in glycopeptide antibacterialsJohn F Barrett
Merck Research Laboratories, Rahway, NJ 07065, USA
Curr Opin Investig Drugs 6:781-90. 2005..Among the leading development candidates are dalbavancin, oritavancin, telavancin and ramoplanin, each of which provides a unique microbiological and pharmacological profile to fill an important unmet medical need...
MRSA: status and prospects for therapy? An evaluation of key papers on the topic of MRSA and antibiotic resistanceJohn F Barrett
Merck Research Laboratories, 126 E Lincoln Avenue, Rahway, NJ 07650, USA
Expert Opin Ther Targets 8:515-9. 2004..Action must be taken to contain and eradicate MRSA through a combination of infection control and the development of novel anti-MRSA agents and vaccines...
Thiazomycins, thiazolyl peptide antibiotics from Amycolatopsis fastidiosaChaowei Zhang
Natural Products Chemistry, Merck Research Laboratories, 126 E Lincoln Avenue, Rahway, New Jersey 07065, USA
J Nat Prod 72:841-7. 2009..The isolation, structure elucidation, antibacterial activity, and proposed biogenesis of thiazomycins are herein described...
Antibacterial evaluations of thiazomycin- a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosaSheo B Singh
Merck Research Laboratories, Rahway, New Jersey, USA
J Antibiot (Tokyo) 60:565-71. 2007..Despite its positive attributes, emergence of an unacceptable frequency of resistance poses significant challenges for further development of thiazomycin and this class of molecules for therapeutic use...
Isolation, structure, and antibacterial activity of thiazomycin A, a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosaChaowei Zhang
Merck Research Laboratories, Rahway, NJ 07065, USA
Bioorg Med Chem 16:8818-23. 2008..7 microg/mL) and a potent Gram-positive antibacterial agent with minimum inhibitory concentration (MIC) ranging 0.002-0.25 microg/mL. The isolation and structure elucidation and biological activities of thiazomycin A are described...
Discovery of FabH/FabF inhibitors from natural productsKatherine Young
Merck Research Laboratories, Rahway, NJ 07065, USA
Antimicrob Agents Chemother 50:519-26. 2006..aureus. It exhibited a spectrum of antibacterial activity against clinically important pathogens including methicillin-resistant Staphylococcus aureus, Bacillus subtilis, and Haemophilus influenzae...
Isolation, structure, and antibacterial activity of philipimycin, a thiazolyl peptide discovered from Actinoplanes philippinensis MA7347Chaowei Zhang
Merck Research Laboratories, Rahway, New Jersey 07065, USA
J Am Chem Soc 130:12102-10. 2008..The design and execution of the bioassay, the isolation, structure, in vitro and in vivo antibacterial activity, and docking studies of philipimycin and its degradation product are described...
Control and prevention of MRSA infectionsLiangsu Wang
Infectious Disease Research, Merck and Co Inc, Rahway, NJ, USA
Methods Mol Biol 391:209-25. 2007..With the realization that MRSA is now a community problem, there are expanded efforts toward more direct intervention, such as the use of anti-MRSA antibacterials and vaccines, in an attempt to reduce the overall burden of MRSA...
Isolation and structure elucidation of thiazomycin- a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosaHiranthi Jayasuriya
Merck Research Laboratories, Rahway, New Jersey, USA
J Antibiot (Tokyo) 60:554-64. 2007..The isolation and structure elucidation of thiazomycin is herein described...
Antibacterial drug discovery--then, now and the genomics futureRichard L Monaghan
Merck Research Laboratories, 126 E Lincoln Avenue, Rahway, NJ 07065, USA
Biochem Pharmacol 71:901-9. 2006..g., host metabolism differences), safety and the microbial genesis of chronic diseases (e.g., gastric ulceration)...
Antibiotics: where did we go wrong?Karen M Overbye
Antibacterial Discovery, Department of Infectious Diseases, Merck Research Laboratories, 126 East Lincoln Avenue, Rahway, NJ 08876, USA
Drug Discov Today 10:45-52. 2005..This decline in antibacterial drug discovery, coupled with increasing risk as a result of infections caused by drug-resistant bacterial pathogens, represents a clear public health threat...
Can biotech deliver new antibiotics?John F Barrett
Department of Infectious Diseases, Merck Research Laboratories, Rahway, NJ 07065, USA
Curr Opin Microbiol 8:498-503. 2005..So this leaves one with the question of 'can biotech deliver the new antibiotics?'...
Pharmacoeconomics of treatment with the newer anti-Gram-positive agentsLiangsu Wang
Department of Infectious Diseases, Merck Research Laboratories, Rahway, NJ 07065, USA
Expert Opin Pharmacother 7:885-97. 2006..e., spectrum, activity, resistance emergence, efficacy, target, safety) provide a basis for an emerging pharmacoeconomic-based distinction between these newer anti-Gram-positive agents...
Determination of selectivity and efficacy of fatty acid synthesis inhibitorsSrinivas Kodali
Department of Human and Animal Infectious Disease, Merck Research Laboratories, Rahway, New Jersey 07065, USA
J Biol Chem 280:1669-77. 2005..2 to 0.4 microg/ml. Furthermore, the effectiveness, selectivity, and the in vitro and in vivo correlations of BABX as well as other fatty acid inhibitors were elucidated, which will aid in future drug discovery...
What are we looking for in new antibacterials and how do we design it?John F Barrett
Expert Opin Investig Drugs 15:85-8. 2006..To this end, the authors outline a few ideas regarding the changes in approach in order to accomplish these needs, including a fundamental change in the drug discovery process...
Microbial genomics and novel antibiotic discovery: new technology to search for new drugsThomas J Dougherty
Department of Microbiology, Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA
Curr Pharm Des 8:1119-35. 2002..Within this overview, we provide a strategic overview of a sample process for the identification, validation and exploitation of novel antibacterial targets ascertained through a bioinformatics-based genomics drug discovery program...
Antibiotics and pharmacogenomicsDaniel B Davison
Bristol-Myers Squibb Pharmaceutical Research Institute, Lawrenceville, NJ 08534, USA. daniel.davison@ bms.com
Pharmacogenomics 4:657-65. 2003....
Antibacterials: are the new entries enough to deal with the emerging resistance problems?Christine T Barrett
Department of English, Princeton University, Princeton, NJ 08540, USA
Curr Opin Biotechnol 14:621-6. 2003..Although critical for certain resistance niche needs, these agents are unlikely to provide the solution to the requirement for a major novel scaffold class of antibacterials...
Discovery of isoxazolinone antibacterial agents. Nitrogen as a replacement for the stereogenic center found in oxazolidinone antibacterialsLawrence B Snyder
Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
Bioorg Med Chem Lett 14:4735-9. 2004..The synthesis and antibacterial activity of three such ring systems, the benzisoxazolinones, pyrroles, and isoxazolinones is described...
Antimicrobial evaluation of nocathiacins, a thiazole peptide class of antibioticsMichael J Pucci
Achillion Pharmaceuticals, 300 George St, New Haven, CT 06511, USA
Antimicrob Agents Chemother 48:3697-701. 2004..These compounds demonstrated potential for further development as a new class of antibacterial agents with activity against key antibiotic-resistant gram-positive bacterial pathogens...
Conserved fungal genes as potential targets for broad-spectrum antifungal drug discoveryMengping Liu
Bristol-Myers Squibb Company Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
Eukaryot Cell 5:638-49. 2006..This work therefore demonstrates a streamlined process for proceeding from selection and validation of candidate antifungal targets to screening for specific inhibitors...
Functional genomics of gram-positive microorganismsMarta Perego
Division of Cellular Biology, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA
J Bacteriol 186:903-9. 2004
Patent alertPeter Norman
Noman Consulting, Burnham, Bucks, UK
IDrugs 7:390-5. 2004
Sordaricin antifungal agentsClaude A Quesnelle
Bristol Myers Squibb Pharmaceutical Research Institute, 100, boul de l Industrie, Candiac, Quebec, Canada J5R 1J1
Bioorg Med Chem Lett 13:519-24. 2003..The synthesis of homologated sordaricin as well as ether and ester derivatives is presented, and structural rearrangement products upon oxidation. These compounds were evaluated as agents to inhibit fungal growth...
Oxime derivatives of sordaricin as potent antifungal agentsMichael H Serrano-Wu
Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
Bioorg Med Chem Lett 12:943-6. 2002..06 microg/mL. The antifungal activity was established to be exquisitely sensitive to the spatial orientation of the lipophilic side chains...
Biaryl isoxazolinone antibacterial agentsClaude A Quesnelle
Bristol Myers Squibb Pharmaceutical Research Institute, Discovery Chemistry, Candiac, Quebec, Canada
Bioorg Med Chem Lett 15:2728-33. 2005..Extensive investigation of various substitutions on the phenyl ring was then undertaken. We report here, the synthesis and antibacterial activity of a series of biaryl isoxazolinone compounds...
